GlassScriptPhysician profile
Morteza Mirhaidari
NPI 1598775280
$597.51
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $124.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $142.80 | 2019 | |
| Polarityte, INC. | $106.46 | 2019 | |
| Rock Medical Orthopedics, INC. | $83.90 | 2019 | |
| Paragon 28, INC. | $70.19 | 2019 | |
| Depuy Synthes Sales INC. | $65.00 | 2020 | |
| Convatec INC. | $58.94 | 2020 | |
| Novo Nordisk INC | $58.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morteza Mirhaidari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.